Effect of PPAR-gamma agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes and coronary artery disease

Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk

(2016) Steven K. Malin et al.   EXERCISE AND SPORT SCIENCES REVIEWS

Is There a Role for Visceral Adiposity in Inducing Type 2 Diabetes Remission in Severely Obese Patients Following Biliopancreatic Diversion with Duodenal Switch Surgery?

(2015) Audrey Auclair et al.   OBESITY SURGERY

Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial

(2014) Z. Punthakee et al.   DIABETIC MEDICINE

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Metformin and Exercise in Type 2 Diabetes: Examining treatment modality interactions

(2011) N. G. Boule et al.   DIABETES CARE

The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes

(2009) J. S. Nam et al.   DIABETIC MEDICINE

AMPK and PPARδ Agonists Are Exercise Mimetics

(2008) Vihang A. Narkar et al.   CELL